小口径脱细胞基质人工血管移植的研究

目的 探讨脱细胞基质( DCM)人工血管用于小口径血管移植的可行性.方法 40条雄性杂种犬随机分为DCM、膨体聚四氟乙烯(ePTFE)人工血管及自体颈外静脉3组行右颈总动脉置换术,彩超监测移植物通畅率.术后4、8周活体取材,标本行苏木素-伊红(HE)、免疫组织化学染色及扫描电镜检查.结果 3组移植物1周通畅率(75.0％、64.3％、100.0％)差异无统计学意义(P＞0.05);自体颈外静脉组4、8周通畅率( 100.0％、88.9％)优于DCM组(56.3％、26.7％)及ePTFE组(57.1％、23.1％,P＜0.05),后两组差异无统计学意义(P＞0.05).DCM人工血管4、8周血栓形成面积小于ePTFE人工血管,吻合口内膜内皮化程度高于后者.结论 小口径DCM人工血管在抑制血栓形成及加快内皮化方面优于ePTFE人工血管.     

即穿型人工血管内瘘与普通聚四氟乙烯人工血管内瘘的系统回顾与meta分析

目的:比较即穿型人工血管内瘘与普通PTFE（聚四氟乙烯）人工血管内瘘的通畅率及相关并发症风险。方法:通过检索MEDLINE,Embase 和Cochrane library数据库,中国生物医学文献数据库、中国知网、万方数据库,纳入到2020年3月为止发表的关于即穿型人工血管和普通PTFE人工血管对比研究的文章,提取初级...     

内皮化小口径人工血管的研究

目的 探讨成人大隐静脉内皮细胞(HSVECs)种植到人工血管内表面的可行性.方法 酶消化法获取成人大隐静脉内皮细胞,在体外扩增培养13～15 d,将扩增培养的内皮细胞种植于纤维蛋白胶预衬的聚四氟乙烯(ePTFE)人工血管内表面,继续体外培养9～12 d.在不同的时间点,分别剪取部分内皮化的人工血管,行荧光显微镜和扫描电镜检查.结果 内皮细胞种植于人工血管后,扫描电镜下可见细胞在血管表面黏附、生长、增殖.平均孵育12 d后,人工血管腔面见一层均匀的基质,其表面有内皮细胞单层,内皮细胞排列紧密,呈梭形.结论 成人大隐静脉内皮细胞可以种植到人工血管,在体外增殖形成内皮细胞单层,达到内皮化的效果.     

bFGF预载脱细胞支架构建小口径人工血管的研究

目的目前临床使用的小口径（〈5cm）人工血管因生物相容性差、远期通畅率低，效果不理想。拟通过在脱细胞血管支架表面预载bFGF，制备一种新型的小口径人工血管。方法采用去污剂一酶消化法制备犬颈动脉脱细胞支架，将bFGF预载在经肝素固化（肝素固化组）和未固化的（单脱细胞组）脱细胞支架表面，ELISA法检测结合的bFGF量及体外释放情况。通过与犬BMSCs体外复合培养1～5d，观察bFGF预载肝素固化脱细胞支架（bFGF预载组）和未固化的脱细胞支架（未预载组），以及各自空白对照组细胞生长情况。取8只杂交犬，切断并剪下颈总动脉造成约5cm缺损，随机选取一侧，将预载组支架行端端吻合于缺损中，作为实验侧；将未预载组支架以同样方法植入对侧，作为对照侧。术后8周取材行DSA、HE染色观察移植效果。结果犬颈动脉经脱细胞后大体形态完好、细胞基本去除、纤维结构完整。肝素固化组支架表面结合的bFGF量与bFGF反应浓度成正相关，与相同反应浓度下单脱细胞组比较差异有统计学意义（P〈0．05）；肝素固化组在浓度为100ng／mL下结合的bFGF可在体外持续释放20d。bFGF预载支架促进BMSCs增殖，MTT显示BMSCs在两组支架表面均可黏附生长，复合培养1、2d两组差异无统计学意义（P〉0．05）：3～5d，bFGF预载组支架表面细胞增殖活性明显高于未预载组（P〈0．01）。异体犬颈动脉移植后8周，实验侧支架均通畅，且有细胞覆盖内膜及浸润管壁，而对照侧通畅率仅为12．5％（1／8），闭塞的移植物腔内均为血栓形成，未见细胞覆盖。结论对同种异体血管脱细胞支架表面进行bFGF预载，初步获得一种具有良好生物相容性和通畅性的生物人工血管，其远期通畅率及生物安全性仍待进一步评价。     

携带eNOS基因的小口径人工血管在犬的体内研究

目的 观察转染内皮型一氧化氮合酶(eNOS)基因的内皮细胞(EC)种植小口径人工血管在实验犬体内的通畅效果.方法 采用"高压灌注两步法"将转染eNOS基因的EC种植于3 mm人工血管;并植入实验犬股动脉,分1、4、12、24周行数字减影血管造影(DSA)、扫描电镜和透射电镜观察植入后情况.结果 转染eNOS基因的EC种植3 mm人工血管,贴附率在90%以上;10 d左右延伸为一层完整连续的内膜.植入犬体内后1周,单纯人工血管组1/3(3/9)血管阻塞;术后4周,单纯人工血管组全部阻塞(9/9),未转染组近半数阻塞(5/10、4/9);术后12周,单纯人工血管组全部阻塞,未转染组几乎全部阻塞(9/9、9/10);术后24周,未转染组全部阻塞,eNOS转染组8/10通畅.电镜检查表明,eNOS转染组人工血管腔面EC排列紧密,形成一层连续完整的内膜,仅见少许红细胞、血小板及白细胞沉积.结论 转染eNOS基因的EC种植小口径人工血管效果满意,植入实验犬体内后通畅效果良好.     

肝素涂层人工血管在腔内治疗失败的严重下肢缺血血运重建中的应用

目的:评价肝素涂层人工血管在腔内治疗失败的严重下肢缺血(CLI)患者行下肢动脉旁路移植术中的疗效。方法:回顾性分析2017年10月至2019年4月北京医院血管外科收治的腔内治疗失败的CLI患者行下肢动脉旁路移植术治疗的临床资料,根据患者临床症状、病变特点,选择个性化治疗方案,包括支架取出术、动脉内膜剥脱和成形术、人工血管或人工血管复合自体静脉旁路移植术等多种手术方式完成下肢动脉血运重建。分析围术期并发症、症状缓解和溃疡伤口愈合情况、桥血管通畅率及保肢率。结果:入组患者共27例,其中16例静息痛患者术后疼痛均有效缓解,11例有足部溃疡和组织坏死者中,9例完全愈合,2例术后半年溃疡面缩小。术后并发症6例,术后30 d无死亡病例。所有患者获得随访,随访时间为(13.0±8.9)个月(范围:2~35个月)。通过Kaplan-Meier曲线计算,术后6、12及24个月一期通畅率分别为83.3%、73.7%及49.1%;二期通畅率分别为91.8%、82.1%及70.8%;保肢率分别为91.8%、86.9%及76.6%。其中15例股-腘动脉旁路移植术术后1、2年一期通畅率分别为86.7%、49.5%;二期通畅率分别为93.3%、81.7%;保肢率分别为93.3%、81.7%。8例股-小腿动脉旁路移植术术后1、2年一期通畅率分别为45.0%、45.0%;二期通畅率分别为58.3%、58.3%;保肢率分别为58.3%、58.3%。结论:肝素涂层人工血管动脉旁路移植术为腔内治疗失败的下肢动脉复杂病变提供了一种安全有效的治疗方式,能够有效缓解症状及提高保肢率。     

人脐静脉小口径人造血管肝素缓释机制的建立及早期抗栓性的研究

本文报道利用新鲜人脐带静脉制各具有肝素缓释机制的人造血管的方法，并与经典法及快速法比较其肝素缓释时效，在试管及动物实研中证实其有效的抗栓性，本研究提示人脐静脉人造血管经肝素伪饰其内壁后可提高其血液相容性及抗栓性。内径４ｍｍ的ＨＵＶＧ经肝素伪饰后用于周围动脉替代及新生儿体肺分流手术可能提高其早期通畅率。     

增强型生物活性玻璃-胶原复合支架材料的成骨效能研究

目的 探讨增强型生物活性玻璃-胶原复合支架材料的体内外成骨效能.方法取第3代BMSCs种植于支架材料(支架组),以等量细胞常规培养作为非支架组,培养1、3、5、7、9、11 d采用阿尔玛蓝法动态检测细胞的增殖率.取第3代BMSCs种植于支架材料(体外实验组),以等量细胞常规培养作为体外对照组,培养4、7 d采用实时定量逆转录聚合酶链式反应(qRT-PCR)检测细胞骨形态发生蛋白-2(BMP-2)、碱性磷酸酶(ALP)、Ⅰ型胶原的mRNA表达.裸鼠皮下植入复合成骨样细胞的支架材料(体内实验组),取正常骨组织作为体内对照组,6周后以X线片、qRT-PCR、绀织学染色评估成骨情况.结果培养7～11 d支架组细胞增殖率显著高于非支架组,差异均有统计学意义(P<0.05).体外实验组培养7 d BMP-2、ALP、Ⅰ型胶原的mRNA表达显著高于体外对照组,差异均有统计学意义(P<0.05).体内实验组X线片示植入区域有密度增高影,支架材料形成白色硬性组织;BMP-2、Ⅰ型胶原、骨钙素、骨桥蛋白的mRNA表达较体内埘照组均增高,差异有统计学意义(P<0.05);组织学染色示支架材料大部分降解,新生骨形成明显.结论增强型生物活性玻璃-胶原复合支架材料具有良好的生物相容性,体内外均具有成骨效应.

Abstract：

Objective To study the in vivo and vitro biocompatibility and osteogenetic capacity of enhanced bioactive glass/collagen composite scaffold. Methods Bone marrow stromal cells(BMSCs)were collected and induced to osteoblast-like cells.The growth rate of BMSCs was detected and compared progressively through Alamar Blue.The RNAs of the cells were collected and detected for bone morphogenetic protein-2(BMP-2),alkaline phosphatase(ALP),collagen Ⅰ(Col-Ⅰ)through qRT-PCR on the fourth and seventh days.Scaffolds with induced osteoblasts were embedded into 3 nude mice subcutaneously in vivo and detected after 6 weeks.X-ray,qRT-PCR and tissue staining were used to detect the mRNA expressions of BMP-2,Col Ⅰ,osteocalcin(OCN)and ostcopontin(OPN)and bone formation. Results SEM(scanning electronic microscopy)showed BMSCs attached to the scaffold tightly and viably and proliferated actively on the scaffold.The growth rate in the experimental group was significantly higher after 7 days(P<0.05)than in the control group.qRT-PCR showed that the mRNA expressions of BMP-2,ALP and Col-Ⅰ in the experimental group were significantly higher than in the control group on the seventh day(P<0.05).X-ray showed that the dense images of embedded scaffolds were locally similar to those of normal bone after 6 weeks.qRT-PCR showed that the mRNA expressions of BMP-2,Col Ⅰ,OCN and OPN in the experimental group were significantly higher than those of normal bone(P<0.05).HE and Massort staining of the paraffin sections showed the scaffolds degraded generally and osteoblasts and chondrocytes proliferated abundantly and distributed irregularly.Bone formation could be observed obviously. Conclusion Enhanced bioactive glass/collagen composite scaffolds have good biocompatibility and osteogenetic capacity in vitro and vivo.     

增强型生物活性玻璃-胶原复合支架材料的成骨效能研究

Objective To study the in vivo and vitro biocompatibility and osteogenetic capacity of enhanced bioactive glass/collagen composite scaffold. Methods Bone marrow stromal cells(BMSCs)were collected and induced to osteoblast-like cells.The growth rate of BMSCs was detected and compared progressively through Alamar Blue.The RNAs of the cells were collected and detected for bone morphogenetic protein-2(BMP-2),alkaline phosphatase(ALP),collagen Ⅰ(Col-Ⅰ)through qRT-PCR on the fourth and seventh days.Scaffolds with induced osteoblasts were embedded into 3 nude mice subcutaneously in vivo and detected after 6 weeks.X-ray,qRT-PCR and tissue staining were used to detect the mRNA expressions of BMP-2,Col Ⅰ,osteocalcin(OCN)and ostcopontin(OPN)and bone formation. Results SEM(scanning electronic microscopy)showed BMSCs attached to the scaffold tightly and viably and proliferated actively on the scaffold.The growth rate in the experimental group was significantly higher after 7 days(P<0.05)than in the control group.qRT-PCR showed that the mRNA expressions of BMP-2,ALP and Col-Ⅰ in the experimental group were significantly higher than in the control group on the seventh day(P<0.05).X-ray showed that the dense images of embedded scaffolds were locally similar to those of normal bone after 6 weeks.qRT-PCR showed that the mRNA expressions of BMP-2,Col Ⅰ,OCN and OPN in the experimental group were significantly higher than those of normal bone(P<0.05).HE and Massort staining of the paraffin sections showed the scaffolds degraded generally and osteoblasts and chondrocytes proliferated abundantly and distributed irregularly.Bone formation could be observed obviously. Conclusion Enhanced bioactive glass/collagen composite scaffolds have good biocompatibility and osteogenetic capacity in vitro and vivo.     

bBMP/胶原/珊瑚复合人工骨修复股骨头骨缺损的实验研究

目的　研究用复合人工骨治疗股骨头坏死的效果。方法　建立双侧股骨头内骨缺损模型 ,并分为 4组 :bBMP/胶原 /珊瑚复合人工骨组 (6侧 )、肌骨瓣组 (6侧 )、单纯珊瑚组 (2例 )、对照组 (14例 ) ,为上各组的对侧。对植入后 3周、 16周的股骨头行病理学检查、计量组织学分析及四环素荧火标记。结果　 16周后 ,复合人工骨的骨缺损大小、缺损区骨小梁体积、荧光带宽度均与对照组有统计学显著性 ,但 5侧中有 1侧出现继发性骨关节炎。结论　该复合人工骨有较强的传导成骨及诱导成骨作用 ,是修复股骨头骨缺损的良好移植材料 ,但它不能改善缺血坏死股骨头的血供。该股骨头内骨缺损加用 95 %酒精灌注 ,模型近似于股骨头坏死囊性变 ,对于研究股骨头坏死的治疗有较大价值     

膨体聚四氟乙烯缝线替换心瓣膜腱索

目的：验证膨体聚四氟乙烯缝线在心脏瓣膜成形术中行腱索替换的效果。方法：１９９１年６月至１９９８年３月在心瓣膜成形术中采用膨体聚四氟乙烯缝线进行人工腱索替换２３例：替换二尖瓣腱索２８支,三尖瓣腱索１支。结果：病人人武部康复出院。其中１７例随访２￣７８个月,平均１８．５个月。彩色Ｂ超复查显示瓣膜关闭不全完全矫正者６例,仍残存极为以并关闭不全者３例,轻并关闭不全７例,术后仍有中并反流１例,系人工腱索过短     

膨体聚四氟乙烯补片在腹外疝修补中的应用

目的探讨膨体聚四氟乙烯补片在成年人腹外疝手术治疗中的技术操作要点,并评价治疗效果。方法回顾性分析我院1998年至2008年,采用美国Gore公司生产的膨体聚四氟乙烯补片施行平片无张力疝修补术的859例腹外疝患者的I临床资料。其中腹股沟斜疝731例,占85．0％;腹股沟直疝86例,占10．0％;股疝13例,占1．5％;切口疝12例,腹白线疝9例,脐疝8例。结果全部病例手术成功,平均手术时间95min,手术后疼痛轻微,无明显异物感。术后平均住院时间4．6d。随访10个月-60个月,平均30个月,无复发病例。结论平片无张力疝修补术具有安全、经济、简便、复发率低的优点,疗效肯定,临床上基本可以满足各种情况下无张力疝修补手术的需要。     

A polyurethane vascular access graft and a hybrid polytetrafluoroethylene graft as an arteriovenous fistula for hemodialysis: comparison with an expanded polytetrafluoroethylene graft

AIM: We evaluated a polyurethane vascular access graft (TVAG), a hybrid polytetrafluoroethylene graft (hPTFEG), and an expanded polytetrafluoroethylene graft (ePTFEG) for postoperative complications and graft patency in their use as prosthetic devices of vascular access for hemodialysis. METHODS: Between August 1993 and October 2001, we treated 200 patients in whom A-V fistulas were placed by the same surgeon. These were divided into the following four groups according to the type of blood access: 27 cases of ePTFEG, 23 cases of TVAG, 22 cases of hPTFEG, and 128 cases of an autogenous A-V fistula. We calculated the cumulative patency rates by the Kaplan-Meier method, including primary (problem-free) and secondary (revised or functional) patency rates. RESULTS: The hPTFEG group experienced few thromboses. The absence of perigraft edema in the TVAG group permitted the early use of the TVAG within a few postoperative days for hemodialysis. Among the three graft groups, the primary patency was the best in the hPTFEG group (94.7% at 1 year and 86.1% at 2 years), with a significant difference versus the ePTFEG group. In regard to secondary patency, hPTFEG had an excellent patency of 100% at 1 year and 90.9% at 2 years, and TVAG had a comparable patency with that of ePTFEG. CONCLUSION: The hPTFEG was considered superior to ePTFEG in terms of being complication-free and had the excellent 2 year secondary patency of 90.9%. TVAG, with a patency equal to that of ePTFEG, could be used immediately after implantation due to the absence of limb edema.     

Evolution of pulmonary valve reconstruction with focused review of expanded polytetrafluoroethylene handmade valves

OBJECTIVESMany surgeons develop unique techniques for unmet needs for right ventricular outflow reconstruction to resolve pulmonary regurgitation after corrective surgery for congenital heart diseases. Expanded polytetrafluoroethylene (ePTFE) stands out as a reliable synthetic material, and clinical results with handmade ePTFE valves have been promising. This review focuses on the historical evolution of the use of ePTFE in pulmonary valve replacement and in the techniques for pioneering the translation of the handmade ePTFE trileaflet design for the transcatheter approach.Open in a separate windowMETHODSWe searched for and reviewed publications from 1990 to 2020 in the Pubmed database. Nineteen clinical studies from 2005 to 2019 that focused on ePTFE-based valves were summarized. The evolution of the ePTFE-based valve over 3 decades and recent relevant in vitro studies were investigated.RESULTSThe average freedom from reintervention or surgery in the recorded ePTFE-based valve population was 90.2% at 5 years, and the survival rate was 96.7% at 3 years.CONCLUSIONSNon-inferior clinical results of this ePTFE handmade valve were revealed compared to allograft or xenograft options for pulmonary valve replacement. Future investigations on transferring ePTFE trileaflet design to transcatheter devices should be considered.     

国产膨体聚四氟乙烯在整形美容外科中的应用

目的评估国产膨体聚四氟乙烯(ePTFE)在整形美容外科中的临床效果. 方法采用国产ePTFE,以进口ePTFE作为对照,根据不同需要分别置于额部、颞部、鼻部、颏部、鼻基底及上颌部,矫正面部软组织缺损及凹陷畸形,比较2组术后伤口愈合、不良反应及临床效果. 结果试验组16例18个部位,术后随访6～9个月,其中1例(鼻部)因埋置过浅、过于接近切口继发感染而取出;1例(颏部)伤口愈合不良,假体外露,经换药后术后2周Ⅱ期愈合;其余病例临床观察未见明显过敏反应、炎症反应及排异反应,外形保持良好,满意率94.4%(17/18).对照组10例12个部位,术后随访6～9个月,1例(鼻部)假体外露取出,其余病例未出现异常情况,满意率为91.7%(11/12).2组在伤口愈合情况(χ2=1.109,P=0.574)、不良反应(P=1.000)和临床疗效(P=1.000)等方面均无显著性差异. 结论国产ePTFE具有良好的组织相容性,适合充填软组织,可作为安全而廉价的替代产品.     

Implantation of decellularized small-caliber vascular xenografts with and without surface heparin treatment

Heparin treatment of decellularized xenografts has been reported to reduce graft thrombogenicity. However, little is known about the in vivo comparison of heparin-treated with non-heparin-treated xenografts, especially for small-caliber vascular implants. We implanted either a heparin-treated or a non-heparin-treated canine carotid artery as bilateral carotid xenograft in rabbits (n = 24). Small-caliber xenografts (3 approximately 4 mm) were decellularized by enzymatic and detergent extraction and were further covalently linked with heparin. During implantation, thrombosis rate was 4% in the heparin-treated xenografts and 25% in the non-heparin-treated xenografts after 3 weeks (P < 0.05). After 6 months, it was 8 versus 58%, respectively (P < 0.01). Both heparin-treated and non-heparin-treated xenografts harvested at the end of 3 and 6 months showed a satisfactory cellular reconstruction of either smooth muscle cells or endothelial cells. These results indicate that heparin treatment of the small-caliber decellularized xenograft reduces the in vivo thrombogenicity. Both heparin-treated and non-heparin-treated xenografts seem to undergo a similar cellular remodeling process up to 6 months.     

膨体聚四氟乙烯充填修复单侧唇腭裂面中份凹陷畸形

目的:探讨膨体聚四氟乙烯(e-PTFE)充填修复单侧唇腭裂患者面中份凹陷畸形的可行性和治疗效果。方法:2002年6月至2005年6月,收治了15例无法接受正颌正畸治疗的单侧唇腭裂术后畸形患者,均伴有牙槽突裂,临床表现为严重的面中份凹陷并伴鼻畸形。所有患者首先接受唇裂二期修复术,然后应用膨体聚四氟乙烯充填矫正面中份凹陷畸形,同时行患侧鼻翼软骨悬吊。所有患者随访6～24个月,拍摄术前、术后面部照片并进行比较。结果:术后患者面中份凹陷畸形得以矫正,患侧鼻翼基底抬高,面形对称,鼻外形有了明显改观,面容改善显著。结论:无条件接受正颌正畸治疗的唇腭裂患者,可从美容角度应用膨体聚四氟乙烯充填整复面中份凹陷畸形,方法简单可靠。     

Effect of collagen and elastin content on the burst pressure of human blood vessel seals formed with a bipolar tissue sealing system

Background

Bipolar devices are routinely used to seal blood vessels instead of sutures and clips. Recent work examining the impact of vascular proteins on bipolar seal performance found that collagen and elastin (CE) content within porcine arteries was a significant predictor of a vessel's burst pressure (VBPr). This study examined seal performance across a range of human blood vessels to investigate whether a similar relationship existed. In addition, we compared VBPr and CE content between porcine and human blood vessels. Our primary hypothesis is that higher collagen-to-elastin ratio will predict higher VBPr in human vasculature.

Methods

In six cadavers, 185 blood vessels from nine anatomic locations were sealed using a bipolar electrosurgical system. A linear mixed model framework was used to evaluate the impact of vessel diameter and CE content on VBPr.

Results

The effect of CE ratio on VBPr is modified by vessel size, with CE ratio having larger influence on VBPr in smaller diameter vessels. Seal burst pressure of vessels 2–5 mm in diameter was significantly associated with their CE content. Comparison of average VBPr between species revealed porcine carotid and iliac arteries (440–670 mmHg) to be the best vessel types for predicting the seal strength of most human blood vessels (420–570 mmHg) examined.

Conclusions

CE content significantly modified the seal strength of small to medium sized blood vessels but had limited impact on vessels >5 mm.     

肾静脉外支架固定术治疗左肾静脉压迫综合征

目的 探讨肾静脉外支架固定术治疗左肾静脉压迫综合征的临床疗效.方法 左肾静脉压迫综合征患者8例.男7例,女1例.平均年龄16(6～25)岁.血尿病史6～36个月,合并蛋白尿2例.均行彩色多普勒超声检查,左肾静脉狭窄段平均直径2.2 mm、最大流速0.7 m/s,扩张段平均直径8.6 mm、最大流速0.2 m/s,扩张段与狭窄段直径比值均3(正常比值<2).CT三维血管重建检查5例示腹主动脉与肠系膜上动脉夹角30°～40°(正常值45°～60°).膀胱镜检查5例可见左输尿管口喷血尿.8例均行肾静脉外支架同定术治疗,取一段长5～10 cm、直径1 cm的人造血管纵行切开,环绕左肾静脉一端至肾门,另一端越过肠系膜上动脉与主动脉间夹角形成一隧道样外支架以减轻肾静脉受压.结果 8例手术均顺利完成.平均手术时间150 min.平均术中出血量50ml.术中术后无明显外科并发症,术后恢复顺利,平均9 d出院.肉眼血尿消失6例、减轻2例.彩色多普勒超声检查7例显示左肾静脉血最大流速0.4～0.7 m/s、无明显受压.术后随访2～24个月,平均10个月,除1例时有活动性肉眼血尿、超声检查显示左肾静脉仍有受压征象外,余7例症状消失、尿常规检查正常、超声检查示左肾静脉血流通畅、受压现象消失.结论 左肾静脉外支架固定术采用人造血管环绕肾静脉抵抗肠系膜上动脉压迫,设计巧妙、损伤小、疗效满意,是治疗左肾静脉压迫综合征的理想方法.